Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,312,496
  • Shares Outstanding, K 51,040
  • Annual Sales, $ 34,030 K
  • Annual Income, $ -45,590 K
  • 60-Month Beta N/A
  • Price/Sales 97.46
  • Price/Cash Flow N/A
  • Price/Book 11.87
Trade KYMR with:

Options Overview

Details
  • Implied Volatility 62.05%
  • Historical Volatility 52.71%
  • IV Percentile 1%
  • IV Rank 5.78%
  • IV High 123.88% on 05/18/21
  • IV Low 58.26% on 09/15/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 12
  • Volume Avg (30-Day) 177
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 193

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.27
  • Number of Estimates 5
  • High Estimate 0.08
  • Low Estimate -0.55
  • Prior Year -0.39
  • Growth Rate Est. (year over year) +30.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.08 +20.21%
on 08/19/21
67.59 -12.71%
on 09/10/21
+6.85 (+13.14%)
since 08/17/21
3-Month
42.34 +39.35%
on 06/30/21
67.59 -12.71%
on 09/10/21
+11.34 (+23.79%)
since 06/17/21
52-Week
27.65 +113.38%
on 10/02/20
91.92 -35.81%
on 12/28/20
+29.98 (+103.31%)
since 09/17/20

Most Recent Stories

More News
5 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock Now

New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups should drive sales of Vertex's (VRTX) cystic fibrosis drug, Trikafta sales higher.

VRTX : 187.47 (+0.20%)
MRNA : 421.09 (-4.44%)
CRSP : 117.55 (+0.11%)
KYMR : 59.64 (-8.10%)
Vertex (VRTX) Inks New Deal for CRISPR Gene-Editing Rights

Vertex (VRTX) collaboration with Arbor will support discovery & development of new treatment options for serious diseases using the latter's CRISPR technology.

VRTX : 187.47 (+0.20%)
MRNA : 421.09 (-4.44%)
CRSP : 117.55 (+0.11%)
KYMR : 59.64 (-8.10%)
Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the...

JPM : 158.24 (+0.09%)
MS : 102.32 (-0.15%)
KYMR : 59.64 (-8.10%)
Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the...

JPM : 158.24 (+0.09%)
MS : 102.32 (-0.15%)
KYMR : 59.64 (-8.10%)
Company News for Jun 29, 2021

Companies in the news are: NTLA, AVXL, MNKD, KYMR

MNKD : 4.47 (-1.97%)
AVXL : 17.31 (+2.00%)
NTLA : 147.12 (-4.37%)
KYMR : 59.64 (-8.10%)
Kymera Therapeutics Announces Proposed Public Offering of Common Stock

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that...

JPM : 158.24 (+0.09%)
MS : 102.32 (-0.15%)
KYMR : 59.64 (-8.10%)
Thinking about buying stock in Iterum Therapeutics, Kymera Therapeutics, Senseonics, Avrobio, or ChemoCentryx?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ITRM, KYMR, SENS, AVRO, and CCXI.

SENS : 3.80 (-0.52%)
AVRO : 6.39 (+1.27%)
CCXI : 16.19 (+1.25%)
ITRM : 0.5919 (-1.35%)
KYMR : 59.64 (-8.10%)
Kymera Therapeutics Presents Positive Late-Breaking Data from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology 2021 Annual Meeting

Data provide further evidence for the central role of IRAK4 in inflammation in hidradenitis suppurativa and support both the degrader rationale for targeting IRAK4 and KT-474 development

BKDCF : 0.4700 (+3.16%)
KYMR : 59.64 (-8.10%)
Vyant Bio Announces Newly Appointed Board of Directors

Vyant Bio, Inc. (the "Company") (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery of...

VYNT : 2.44 (+1.67%)
KYMR : 59.64 (-8.10%)
NANO : 35.33 (-0.81%)
LQDA : 2.64 (-0.38%)
IDRA : 1.0200 (+0.49%)
SNDX : 19.80 (+2.54%)
RSI Alert: Kymera Therapeutics (KYMR) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

KYMR : 59.64 (-8.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

See More

Key Turning Points

3rd Resistance Point 68.41
2nd Resistance Point 67.03
1st Resistance Point 65.96
Last Price 59.64
1st Support Level 63.51
2nd Support Level 62.13
3rd Support Level 61.06

See More

52-Week High 91.92
Fibonacci 61.8% 67.37
Fibonacci 50% 59.78
Last Price 59.64
Fibonacci 38.2% 52.20
52-Week Low 27.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar